title: A point of view: HIV-1/AIDS is an allergy but CpG ODN treatments may inhibit virus replication and reactivate the adaptive immunity--hypothesis and implications.
abstract: Reevaluation of the increase in the levels of IgE and IL-4 in sera of HIV-1 infected and AIDS patients led to the suggestion that AIDS resembles allergy. Studies on the properties of the viral shed gp120 revealed that it resemble environmental allergens in their ability to induce hematopoietic cells to release large amounts of Th2 cytokines, inhibitors of the patients adaptive immune response. Yet, induction of TLR9+ plasmacytoid DCs by CpG ODNs cause the release of type I interferons, inhibitors of HIV-1 replication and IL-4 release from hematopoietic cells. CpG ODN binding to TLR+ B cells inhibits IgE synthesis and reactivates the failing adaptive immunity. The possible use of CpG ODNs as treatment to patients is discussed.
authors.affiliation: Department of Molecular Virology, Faculty of Medicine, Hebrew University of Jerusalem, P.O.B. 12272, Jerusalem 91120, Israel. becker@md.huji.ac.il
authors.forename: Yechiel
authors.initials: Y
authors.lastname: Becker
mesh_terms: D016915:AIDS Vaccines; D000276:Adjuvants, Immunologic / Q000494:pharmacology / Q000627:therapeutic use; D015699:HIV Envelope Protein gp120 / Q000276:immunology; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology* / Q000517:prevention & control; D015497:HIV-1 / Q000187:drug effects / Q000276:immunology / Q000502:physiology*; D006801:Humans; D006967:Hypersensitivity; D007113:Immunity, Innate; D007073:Immunoglobulin E / Q000097:blood; D009838:Oligodeoxyribonucleotides / Q000494:pharmacology* / Q000627:therapeutic use*; D014779:Virus Replication / Q000187:drug effects
chemical_list: D016915:AIDS Vaccines; D000276:Adjuvants, Immunologic; C408982:CPG-oligonucleotide; D015699:HIV Envelope Protein gp120; D009838:Oligodeoxyribonucleotides; D007073:Immunoglobulin E
references.citation: Curr Opin Microbiol. 2003 Oct;6(5):472-7
references.pmid: 14572539
references.citation: J Biol Chem. 1994 Sep 16;269(37):23087-94
references.pmid: 7521875
references.citation: Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3348-52
references.pmid: 2014254
references.citation: Virus Genes. 2004 Aug;29(1):147-65
references.pmid: 15215692
references.citation: J Allergy Clin Immunol. 2002 Nov;110(5):706-12
references.pmid: 12417878
references.citation: Clin Immunol Immunopathol. 1983 Jun;27(3):315-25
references.pmid: 6223758
references.citation: Science. 2004 Feb 27;303(5662):1294-7; author reply 1294-7
references.pmid: 14988536
references.citation: Virus Genes. 2004 Apr;28(3):319-31
references.pmid: 15266113
references.citation: Virus Genes. 2004 Jan;28(1):5-18
references.pmid: 14739648
references.citation: J Virol. 2002 Nov;76(22):11397-404
references.pmid: 12388700
references.citation: J Allergy Clin Immunol. 2001 Sep;108(3):417-23
references.pmid: 11544462
references.citation: Curr Opin Immunol. 2002 Jun;14(3):373-9
references.pmid: 11973137
references.citation: Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7681-6
references.pmid: 10884399
references.citation: Lancet. 2002 Jul 6;360(9326):73-7
references.pmid: 12114060
references.citation: Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8852-5
references.pmid: 1528902
references.citation: J Immunol. 2000 Nov 15;165(10):5472-9
references.pmid: 11067899
references.citation: Blood. 2003 Dec 15;102(13):4487-92
references.pmid: 12946990
references.citation: Virus Genes. 2003 Dec;27(3):269-82
references.pmid: 14618088
references.citation: Immunol Today. 1993 Mar;14(3):107-11
references.pmid: 8096699
references.citation: J Immunol. 2003 Apr 1;170(7):3898-905
references.pmid: 12646659
references.citation: Science. 2003 Jun 27;300(5628):2036-9
references.pmid: 12829768
references.citation: Nat Med. 2004 Mar;10(3):221-3
references.pmid: 14991035
references.citation: Nat Med. 2003 Jul;9(7):874-80
references.pmid: 12835708